Donate
T1International Statement on Insulin Manufacturer's Responses to COVID-19

T1International Statement on Insulin Manufacturer's Responses to COVID-19

Facebook Google LinkedIn Twitter

Over the last week, in response to the COVID-19 pandemic, both Eli Lilly and Novo Nordisk have announced measures to offer insulin at low cost to patients who have been adversely affected by the outbreak and corresponding economic fallout. These announcements are a significant wins for #insulin4all advocates across the nation, showing that pharma-free patient advocacy is worthwhile and does result in positive change. However, these measures are also a gut-punch for people living with diabetes. 

With each vial of insulin being manufactured for as little as four dollars and the current formula being decades old, the enormously profitable insulin manufacturers had the power to make these changes many years ago. So why didn’t they take these measures sooner? People with diabetes have been suffering and dying from lack of affordable insulin for many years. It shouldn’t take a global health crisis to spur real action on this issue. The companies should have made these moves when Eli Lilly Executives met with Nicole Smith-Holt back in 2018, or hearing from many family members who lost their loved ones last year, or meeting with an #insulin4all advocate who urged the essential need for lower list prices.

We have said since day one that no patient should have to jump through hoops or spend extra time trying to access the essential medication they have a right to. Millions of Americans have recently lost their jobs, families have been burdened with additional responsibilities, and patients with diabetes in particular must take extra steps to safeguard themselves against a virus that is made more serious and deadly by their underlying condition. With this exceptional level of stress and worry on everyone’s plate, patients should not have to call a helpline or jump through more hoops to ask for help. Why not lower the list price and make insulin affordable at the counter? Why put a further burden on patients who are already struggling?

There is no denying that the COVID-19 crisis is critical. But the virus has also brought into sharp focus the existing problems with American healthcare. Patients with diabetes were already dealing with a crisis before coronavirus became a pandemic, and that crisis was caused by companies that sought to rake in huge profits off the backs of patients, even as an ever-increasing number of stories of insulin rationing and patient deaths came to light.

The measures announced by Eli Lilly and Novo Nordisk will not help everyone. By Lilly’s own admission, patients with government insurance such as Medicaid, Medicare, Medicare Part D or any State Patient or Pharmaceutical Assistance Program are not eligible for their program. And for the Novo Nordisk program, through which patients would receive 90 days of insulin at no cost, only patients that have lost their jobs due to the coronavirus pandemic qualify. A solution that works for all of us is essential. Patients with diabetes have suffered too long from the profiteering of pharmaceutical companies. The best way for insulin manufacturers to demonstrate their commitment to patient health would be for them to permanently lower their list price, which would make low-cost insulin easier to acquire and apply to every patient who needs it. That is the path to these actions being real contributions to public health, and not just savvy PR moves while the world’s and media’s attention is on the pandemic.

Until affordable insulin is a lasting reality for all, T1International and patient advocates across the country and the world will continue our work for genuinely affordable insulin and supplies for all, without the influence of pharmaceutical company funding swaying our advocacy.

Related posts:

T1International Statement on COVID-19

T1International Statement on COVID-19

As the world grapples with the effects of a global pandemic, the situation is evolving quickly and the short and long-term impacts are still unclear. What is clear is that the COVID-19 crisis stresses the need to approach healthcare as a human right. The crisis also emphasizes the need for international cooperation to fix global health problems. There must be global solidarity in the fight for #insulin4all and universal access to healthcare. Read more

T1International Statement on Brexit

T1International Statement on Brexit

We stand ready to hold the UK government to account on the provision of healthcare for UK citizens with type 1 diabetes over the coming months and years. We will strongly resist any erosion of the current provision of essential medicine and supplies, medical devices or support services for patients with type 1 diabetes in the UK. Read more

T1International Statement on Lilly & Novo's ''Generic Insulin''

T1International Statement on Lilly & Novo's ''Generic Insulin''

Patient-led activism is working. Today Eli Lilly announced that in response to criticism of high prices, the company will sell a version of Humalog insulin for half price. We are pleased to see this result after continual and dedicated efforts by non-pharma funded patient advocates to ensure list price of insulin goes down. While half-price is an improvement, it's still an unaffordable price for so many, considering most people need at least 2 vials each month.
Read more

T1International Statement on Novo Nordisk and Sanofi Price Hikes

T1International Statement on Novo Nordisk and Sanofi Price Hikes

Sanofi and Novo Nordisk are celebrating the New Year with fresh price hikes on their decades-old insulin products. “Sanofi increased the price of its three main insulin brands by between 4.4 %- 5.2 % last week, while Novo Nordisk increased the price of its insulin products by just under 5% on Tuesday,” the Financial Times article said. Once again, shareholder profits will be increased on the backs of people with diabetes. Read more

Nicole Smith-Holt Statement on Eli Lilly Helpline Announcement

Nicole Smith-Holt Statement on Eli Lilly Helpline Announcement

I vow to continue to fight for the rights and lives of all people with diabetes. I am doing all this in honor of my son, Alec Raeshawn Smith. I invite Lilly to work with me and non-industry funded organizations like T1International so that we can find real solutions to ensure #insulin4all. Mr. Mason, I am still waiting to hear from you. Read more

T1International Statement on Walmart Insulin

T1International Statement on Walmart Insulin

Recently, the American Diabetes Association issued a white paper on Insulin Access and Affordability by their Working Group. While we continue to applaud the American Diabetes Association for speaking out about the high cost of insulin, we remain concerned with their approach and some of the recommendations in their paper.
Read more

T1International Statement on ADA Insulin Price Petition

T1International Statement on ADA Insulin Price Petition

It is fantastic to see a large diabetes organization speaking out in this way. However, we feel that the ADA’s language around the call for price transparency does not go far enough. Read more